{"organizations": [], "uuid": "49db2ba93273f893d2a03c6c3c358d6709a18e1d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-kite-announces-clinical-collaborat/brief-kite-announces-clinical-collaboration-with-pfizer-idUSFWN1PD133", "country": "US", "domain_rank": 408, "title": "BRIEF-Kite Announces Clinical Collaboration With Pfizer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-18T17:36:00.000+02:00", "replies_count": 0, "uuid": "49db2ba93273f893d2a03c6c3c358d6709a18e1d"}, "author": "", "url": "https://www.reuters.com/article/brief-kite-announces-clinical-collaborat/brief-kite-announces-clinical-collaboration-with-pfizer-idUSFWN1PD133", "ord_in_thread": 0, "title": "BRIEF-Kite Announces Clinical Collaboration With Pfizer", "locations": [], "entities": {"persons": [{"name": "kite", "sentiment": "none"}], "locations": [], "organizations": [{"name": "pfizer reuters staf", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "negative"}, {"name": "gilead sciences inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "gilead sciences inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "kite", "sentiment": "none"}, {"name": "gilead", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 36 PM / Updated 20 minutes ago BRIEF-Kite Announces Clinical Collaboration With Pfizer Reuters Staff 1 Min Read \nJan 18 (Reuters) - Gilead Sciences Inc: \n* KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA \n* GILEAD SCIENCES INC - KITE ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH PFIZER, INC \n* GILEAD SCIENCES INC - MULTI-CENTER PHASE 1/2 STUDY SPONSORED BY KITE IS EXPECTED TO BEGIN IN 2018 \n* GILEAD SCIENCES INC - RESULTS OF STUDY WILL BE USED TO EVALUATE OPTIONS FOR FURTHER DEVELOPMENT OF THE COMBINATION, OR SIMILAR COMBINATIONS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-18T17:36:00.000+02:00", "crawled": "2018-01-18T18:06:54.001+02:00", "highlightTitle": ""}